Hyperlipidemia

Primary Care - Clinics in Office Practice

Volumn 27, Issue 3, 2000, Pages 541-587

  Yu, Jack N ^a,b,c,d   Cunningham, Janet A ^a,b   Thouin, Sheryl Rosenberg ^a   Gurvich, Tatyana ^a   Liu, Davis ^a  

^a Glendale Adventist Medical Center   (United States)

^b LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CHOLESTIN; CLOFIBRATE; COLESTIPOL; COLESTYRAMINE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; WARFARIN;

CLINICAL TRIAL; DIET THERAPY; HEART MUSCLE ISCHEMIA; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; META ANALYSIS; MORTALITY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION;

EID: 0033848922     PISSN: 00954543     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0095-4543(05)70164-0     Document Type: Article

References (178)

1. Oxidation of low-density lipoproteins: Intraindividual variability and the effect of dietary linoleate supplementation
2. Cerivastatin for hypercholesterolemia
3. Choice of lipid-lowering drugs
4. Therapeutic actions of garlic constituents
5. The effect of vitamin E and beta-carotene on the incidence of lung cancer and other cancers in male smokers
6. Improving the prediction of coronary heart disease to aid in the management of high cholesterol levels
7. Lowering risk without lowering cholesterol: Implications for national cholesterol policy
8. American College of Physicians: Guidelines for using serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease in adults
9. Consensus statement on heart disease in women
10. Metabolic disturbances increasing the risk of coronary heart disease during diuretic-based antihypertensive therapy: Lipid alteration and glucose intolerance
11. Dietary fiber and heart disease: Current management concepts and recommendations
12. Meta-analysis of the effects of soy protein intake on serum lipids
13. An updated coronary risk profile
14. Effects of lifestyle activity vs structured aerobic exercise in obese women: A randomized trial
15. Discontinuation of antihyperlipidemic drugs - Do rates reported in clinical trials reflect raters in primary care settings?
16. Persistence of use of lipid-lowering medications: A cross-national study
17. Steroid-induced hyperlipidemia. A complication of high-dose corticosteroid therapy
18. Drug treatment of dyslipidemias: Practical guidelines for the primary care physician
19. Omega-3 fatty acids: Panacea?
20. Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne
21. Genetic lipoprotein abnormalities producing high blood cholesterol
22. Changes in plasma cholesterol levels after hospitalization for acute coronary events
23. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of Hyperlipidemias (POSCH)
24. Task for 5: Stratification of patients into high medium and low risk subgroups for purposes of risk factor management
25. The plate model: A visual method of teaching meal planning
26. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low dose anticoagulation on obstructive changes in saphenous vein coronary artery bypass grafts
27. Canadian Task Force on the Periodic Health Examination: Periodic health examination 1993 update: 2. Lowering the blood total cholesterol level to prevent coronary heart disease
28. Incidence of coronary heart disease and lipoprotein levels. The Framingham Study
29. Blood lipid measurements. Variations and practical utility
30. Does lowering cholesterol cause cancer?
31. Adrenergic mechanisms in the control of plasma lipids in man
32. Mediterranean diet: Traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: Final report of the lyon diet heart study
33. Effects of fats high in stearic acid on lipid and lipoprotein concentrations in med
34. Cholesterol-lowering diets: A review of the evidence
35. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/ TexCAPS, Air Force/Texas Coronary Atherosclerosis Prevention Study
36. Serum lipids in normo- and hyperlipidemics after methyldopa and propranolol
37. Statin comparison
38. Family history and premature coronary heart disease
39. Expert Panel: Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II)
40. Lipids in the elderly
41. Avoiding the unintended consequences of growth in medical care - How might more be worse?
42. Statement on trans fatty acids
43. Fat transport in lipoproteins - An integrated approach to mechanisms and disorders
44. Body fat distribution and male/female differences in lipids and lipoproteins
45. Helsinki Heart Study Primary - Prevention trial with gemfibrozil in middle-aged men with dyslipidemia: Safety of treatment, changes in risk factors, and incidence or coronary heart disease
46. Multiclinic comparison of labetalol to metoprolol in treatment of mild-to-moderate systemic hypertension
47. Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATP II) Guidelines
48. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events
49. Cholesterol screening in asymptomatic adults, revisited
50. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction
51. Type of alcoholic beverage and risk of myocardial infarction
52. Soluble fiber and serum lipids: A literature review
53. Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients
54. Identifying adults at increased risk of coronary disease
55. Cost-effectiveness of 3-Hydroxy-3methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease
56. Primary prevention of coronary heart disease guidance from Framingham
57. When to start cholesterol-lowering therapy in patients with coronary heart disease
58. Workshop on the impact of dietary cholesterol on plasma lipoproteins and atherogenesis
59. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome
60. Treating cholesterol in the elderly
61. Oxidation of low-density lipoproteins: Questions of initiation, propagation, and the effect of antioxidants
62. Various intensities of leisure time physical activity in patients with coronary artery disease: Effects on cardiorespiratory fitness and progression of coronary atherosclerotic lesions
63. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease: Estimating the benefits of increasing HDL-C
64. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with HTN principal results of the Hypertension Optimal Treatment (HOT) randomised trial
65. Primary Prevention of CHD: Nine ways to reduce risk
66. Cholesterol lowering with statin drugs, risk of stroke and total mortality
67. Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: A randomized, controlled clinical trial
68. Frequent nut consumption and risk of coronary heart disease in women: Prospective cohort study
69. Significance of cholesterol levels in elderly persons
70. Randomised trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
71. Should we be measuring blood cholesterol levels in young Adults?
72. Communicating the benefits of chronic preventive therapy: Does the format of efficacy data determine patients' acceptance of treatment?
73. Hyperlipidemia
74. Range of serum cholesterol values in the population developing coronary artery disease
75. Fish and heart disease
76. The anti-thrombotic effects of statins
77. LDL-apheresis: Results of long term treatment and vascular outcome
78. Coronary heart disease in seven countries
79. Cholesterol and coronary heart disease: Predicting risks by levels and ratios
80. Alcoholic beverage choice and risk of coronary artery disease mortality: Do red wine drinkers fare best?
81. Cardiovascular risk profiling in blacks: Don't forget the lipids
82. The effect of diet on plasma lipids, lipoproteins, and coronary heart disease
83. Effects of the national cholesterol education program's step I and step II dietary intervention programs on cardiovascular disease risk factors: A meta-analysis
84. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years
85. Lipids
86. Effects of substituting dietary soybean protein and soybean oil for milk protein and milk fat in hypercholesterolemic subjects
87. Cholesterol agnostics
88. Effects of anti hypertensive therapy on plasma lipids and lipo proteins in the multiple risk factor intervention trial
89. Blood cholesterol and walnut consumption: A cross-sectional survey in France
90. Dietary prevention of coronary heart disease: The Lyon diet heart study
91. Antihypertensive drugs and blood lipids: The Oslo study
92. Effect of pravastatin on cardiovascular events in older patients with myocardial infarctions and cholesterol levels in the average range: Results of the cholesterol and recurrent events (CARE) Trial
93. Mortality from coronary heart disease and cardiovascular disease among U.S. Hispanics: Findings from the National Health Interview Study
94. Vascular Disease: Atherosclerosis
95. Trans fatty acids, plasma lipid levels, and risk of developing cardiovascular disease
96. Coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease
97. Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary disease cholesterol lowering
98. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
99. Effects of prazosin on serum lipids in patients with essential hypertension
100. The Lipid Research Clinics Coronary Primary Prevention Trial results. I and II
101. Is heart disease all in the family? Family history and cardiovascular disease
102. Primary prevention of heart disease and stroke: A simplified approach to estimating risk of events and making drug treatment decisions
103. Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy
104. Lipids, lipoproteins, and cardiovascular disease in older women
105. Carcinogenicity of lipid-lowering drugs
106. NIH consensus development panel on triglyceride, high-density lipoprotein, and coronary heart disease: Triglyceride, high-density lipoprotein, and coronary heart disease
107. Individual effects of dietary saturated fatty acids and fish oil on plasma lipids and lipoproteins in normal men
108. Lipid-lowering diets enriched with monounsaturated or polyunsaturated fatty acids but low in saturated fatty acids have similar effects on serum lipid concentrations in hyperlipidemic patients
109. Avoiding revascularization with lifestyle changes: The multicenter lifestyle demonstration project
110. Effects of labetalol on lipid and carbohydrate metabolisms
111. Impact on intensive lipid modulation on angiographically defined coronary disease
112. Niacin hepatitis
113. Hyperlipidemias
114. Dietary reduction of serum cholesterol concentration: Time to think again
115. Number-needed-to-treat analysis of the prevention of myocardial infarction and death by antidyslipidemic therapy
116. Antiatherothrombotic properties of statins
117. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
118. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial
119. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
120. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
121. Lipoproteins, nutrition, aging, and atherosclerosis
122. Physician extenders for cost-effective management of hypercholesterolemia
123. Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy
124. Hepatitis caused by low-dose sustained-release niacin
125. Simvastatin decreases mortality
126. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group
127. Fatty acids and lipids from cell biology to human disease
128. Soybean protein diet and plasma cholesterol: From therapy to molecular mechanisms
129. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT)
130. Bandolier
131. Effects of diet and exercise in men and postmenopausal women with low levels of HDL cholesterol and high levels of LDL cholesterol
132. Fish consumption, fish oil, lipids, and coronary heart disease
133. Dietary palmitic acid results in lower serum cholesterol than does a lauric-myristic acid combination in normolipemic humans
134. Task Force on Risk Reduction: AHA cholesterol screening in asymptomatic adults, no cause to change
135. Fat high in stearic acid favorably affects blood lipids and factor VII coagulant activity in comparison with fats high in palmitic acid or high in myristic and lauric acids
136. Antioxidant consumption and risk of coronary heart disease: Emphasis on vitamin C, vitamin E, and beta-carotene
137. AHA Neducak/Scientific Statement. Fiber, lipids, and coronary heart dis ease: A statement for healthcare professionals from the nutrition committee, American Heart Association
138. The effect of dietary omega-3 fatty acids on coronary atherosclerosis: A randomized, double-blind, placebo-controlled trial
139. Treatment of hyperlipidemia in women
140. Effect of garlic on total serum cholesterol. A meta-analysis
141. Interventions to reduce cardiovascular risk factors in children and adolescents
142. Comparison of captopril and hydrochlorothiazide alone and in combination in mild to moderate essential hypertension
143. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: Final mortality follow-up
144. A cooperative trial in the primary prevention of ischaemic heart disease using clofibrate
145. The effect of fasting status on the determination of low-density and high-density lipoprotein cholesterol
146. Trans fatty acids: Are the effects only marginal?
147. Intake of trans fatty acids and risk of coronary heart disease among women
148. High-density lipoprotein cholesterol and other risk factors for coronary heart disease in female runners
149. Prediction of coronary heart disease using risk factor categories
150. Prevention of coronary heart disease in clinical practice. Recommendations of the second joint task force of European and other societies on coronary prevention
151. The effects on plasma lipoproteins of a prudent weight-reducing diet, with or without exercise, in overweight men and women
152. Dietary trans fatty acids and lipoprotein cholesterol